TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9427706

Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP) infusion at stepwise doses of 0.7, 7.0, and 70 ng/min
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Constant-rate DDAVP infusion at 70 ng/min for 20 minutes
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sodium nitroprusside (SNP) infusion at doses of 0.5, 2.5, and 10 micrograms/min
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control arm (dominant arm) during constant-rate DDAVP infusion
Number of subjects: 15
Study: 8089668

Group type: EXPERIMENTAL
Intervention: Vigabatrin (1.5 g twice daily)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 2682901

Group type: EXPERIMENTAL
Intervention: Amitriptyline hydrochloride
Number of subjects: 170

Group type: COMPARATOR
Intervention: Tryptizol
Number of subjects: 170
Study: 30596581

Group type: EXPERIMENTAL
Intervention: Anode HD-tDCS
Number of subjects: 11

Group type: COMPARATOR
Intervention: Cathode HD-tDCS
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sham HD-tDCS
Number of subjects: 11
Study: 27112096

Group type: EXPERIMENTAL
Intervention: 3 months of treatment by a specialist physiotherapist
Number of subjects: 30

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 30
Study: 25338188

Group type: EXPERIMENTAL
Intervention: Natural context (visual feedback of hand)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Virtual context (computer-generated feedback)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Concurrent feedback
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Terminal feedback
Number of subjects: 40
Study: 24121753

Group type: EXPERIMENTAL
Intervention: Nevirapine
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Nevirapine and Zidovudine
Number of subjects: 491
Study: 22171868

Group type: EXPERIMENTAL
Intervention: Electroacoustic musical composition
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Audio field recordings
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Audio field recordings with embedded binaural beats
Number of subjects: 170

Group type: COMPARATOR
Intervention: Simulated ED ambient noise
Number of subjects: 170

Group type: COMPARATOR
Intervention: Headphones only (control group)
Number of subjects: 170
Study: 19192344

Group type: EXPERIMENTAL
Intervention: Visualization of meiotic spindle
Number of subjects: 10

Group type: COMPARATOR
Intervention: No visualization of meiotic spindle
Number of subjects: 10
Study: 16510658

Group type: EXPERIMENTAL
Intervention: Early Start program of home visitation
Number of subjects: 443

Group type: COMPARATOR
Intervention: Control group (no Early Start program)
Number of subjects: 443
Study: 14631087

Group type: EXPERIMENTAL
Intervention: Hypothermia (33±1 degrees C for 24 hours)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Hypothermia
Number of subjects: 70
Study: 12006146

Group type: EXPERIMENTAL
Intervention: Diskus/Accuhaler
Number of subjects: 169

Group type: COMPARATOR
Intervention: Turbuhaler
Number of subjects: 169
Study: 9596366

Group type: EXPERIMENTAL
Intervention: Insertion of ventilation tubes (VT)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Healthy children with no history of middle ear diseases (Control)
Number of subjects: 64
Study: 7646915

Group type: EXPERIMENTAL
Intervention: Hormonal or chemotherapy
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Radio/chemotherapy
Number of subjects: 27

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 27
Study: 2095312

Group type: EXPERIMENTAL
Intervention: 1.5% hydrogen peroxide mouthrinse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 0
Study: 346356

Group type: EXPERIMENTAL
Intervention: Pindolol 5 mg (single oral dose)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Salbutamol (conventional therapeutic dose by inhalation)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30708998

Group type: EXPERIMENTAL
Intervention: Dat-e Adolescence prevention program
Number of subjects: 1423

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1423
Study: 28787738

Group type: EXPERIMENTAL
Intervention: Manual‐based low‐level psychological intervention
Number of subjects: 119

Group type: COMPARATOR
Intervention: Treatment as usual (weight loss treatment)
Number of subjects: 119
Study: 25702059

Group type: EXPERIMENTAL
Intervention: Dietary alpha-linolenic acid (ALA) intake
Number of subjects: 1009
Study: 23600983

Group type: EXPERIMENTAL
Intervention: Cevimeline 30 mg three times a day for four weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Pilocarpine 5 mg three times a day for four weeks
Number of subjects: 15
Study: 21652750

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 240

Group type: COMPARATOR
Intervention: Salicylic acid
Number of subjects: 240
Study: 19405969

Group type: EXPERIMENTAL
Intervention: High Intensity Treatment (HIT)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Low Intensity Treatment (LIT)
Number of subjects: 300
Study: 16931871

Group type: EXPERIMENTAL
Intervention: Oral clonidine pre-treatment
Number of subjects: 13
Study: 15303766

Group type: EXPERIMENTAL
Intervention: 40 mg isosorbide dinitrate (sustained-release)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 11
Study: 11386765

Group type: EXPERIMENTAL
Intervention: Acutrak screw fixation
Number of subjects: 53

Group type: COMPARATOR
Intervention: Cast immobilisation
Number of subjects: 53
Study: 9422292

Group type: EXPERIMENTAL
Intervention: ondansetron 8 mg
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: droperidol 1.25 mg
Number of subjects: 439

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 439
Study: 8373715

Group type: EXPERIMENTAL
Intervention: Racemic hydroxychloroquine
Number of subjects: 8
Study: 31970477

Group type: EXPERIMENTAL
Intervention: Minodronate (50 mg/4 weeks) plus alfacalcidol (1 μg/day)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Alfacalcidol (1 μg/day)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Minodronate plus alfacalcidol
Number of subjects: 152

Group type: COMPARATOR
Intervention: Alfacalcidol alone
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Both groups (M and A)
Number of subjects: 152
Study: 29549822

Group type: EXPERIMENTAL
Intervention: Social behavioral change communication intervention designed to prevent IPV
Number of subjects: 1435

Group type: EXPERIMENTAL
Intervention: Ward-level PVNS scores
Number of subjects: 1435
Study: 27473346

Group type: EXPERIMENTAL
Intervention: Long-acting methylphenidate (OROS-MPH) prescribed to 38 patients
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Atomoxetine prescribed to 32 patients
Number of subjects: 70

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Hyperactive/impulsive subtype
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Inattentive subtype
Number of subjects: 70
Study: 24809737

Group type: EXPERIMENTAL
Intervention: Pulmonary vein (PV) antral isolation
Number of subjects: 57
Study: 23060624

Group type: EXPERIMENTAL
Intervention: NVA237 50 μg
Number of subjects: 1066

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 μg
Number of subjects: 1066

Group type: COMPARATOR
Intervention: NVA237
Number of subjects: 1066
Study: 20071096

Group type: EXPERIMENTAL
Intervention: Socially evaluated cold pressor test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control procedure
Number of subjects: 0
Study: 18666494

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide with no desensitizers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide with 3% potassium nitrate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide with 0.5% potassium nitrate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide with 0.5% potassium nitrate and 0.25% sodium fluoride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All active bleaching agents (including 10% carbamide peroxide with potassium nitrate)
Number of subjects: 0
Study: 16129870

Group type: EXPERIMENTAL
Intervention: Patient decision aid (self-administered booklet and audiotape tailored to personal stroke risk profile)
Number of subjects: 434

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Patient decision aid
Number of subjects: 434
Study: 12898043

Group type: EXPERIMENTAL
Intervention: TIVA/dimenhydrinate (Group TD)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Volatile/dimenhydrinate (Group VD)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Volatile anaesthesia
Number of subjects: 110
Study: 10786195

Group type: EXPERIMENTAL
Intervention: Topotecan 1.5 mg/m2 on 5 consecutive days every 3 weeks
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Continuous infusion of topotecan 0.3 to 0.5 mg/m2
Number of subjects: 139

Group type: COMPARATOR
Intervention: Topotecan 1.5 mg/m2/day for 5 consecutive days every 21 days
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Topotecan
Number of subjects: 139
Study: 8682118

Group type: COMPARATOR
Intervention: ACE inhibitors
Number of subjects: 3411
Study: 1997045

Group type: EXPERIMENTAL
Intervention: Clonidine 7 micrograms kg‐1 i.v. infusion over 120 min
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 6386760

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy with misonidazole (12 g/m2 daily in 1.2 g/m2 fractions)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Hyperfractionated radiotherapy without misonidazole
Number of subjects: 52
Study: 31767595

Group type: EXPERIMENTAL
Intervention: Collaborative and stepped care model
Number of subjects: 570

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 570
Study: 29947751

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 2199

Group type: COMPARATOR
Intervention: Enoxaparin/warfarin
Number of subjects: 2199
Study: 27018693

Group type: EXPERIMENTAL
Intervention: Paravertebral block with general anesthesia
Number of subjects: 74

Group type: COMPARATOR
Intervention: General anesthesia alone
Number of subjects: 74
Study: 24219336

Group type: EXPERIMENTAL
Intervention: Electric toothbrush (Group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Manual toothbrush (Group A)
Number of subjects: 40
Study: 21837746

Group type: EXPERIMENTAL
Intervention: Intermittent hepatic inflow occlusion (IHIO) during donor hepatectomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no IHIO)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intermittent hepatic inflow occlusion (IHIO)
Number of subjects: 50
Study: 19411388

Group type: EXPERIMENTAL
Intervention: naproxcinod 750 mg once daily (qd)
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: naproxcinod 750 mg twice daily (bid)
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: naproxcinod 1125 mg bid
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: rofecoxib 25 mg qd
Number of subjects: 543

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: naproxcinod 750 mg bid
Number of subjects: 543
Study: 17999010

Group type: EXPERIMENTAL
Intervention: Dynamic ankle-foot orthoses
Number of subjects: 6

Group type: COMPARATOR
Intervention: Typically developing children (Control)
Number of subjects: 6
Study: 14693981

Group type: EXPERIMENTAL
Intervention: Troglitazone (200 mg for 12 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 12351253

Group type: EXPERIMENTAL
Intervention: Magnesium-corrected group (n = 43)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (n = 42)
Number of subjects: 85
Study: 9852438

Group type: EXPERIMENTAL
Intervention: Blue filter treatment (flash stimulation with a blue filter during occlusion of the better eye for one hour daily)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Blue filter treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Classical treatment (full time total occlusion by patch)
Number of subjects: 50
Study: 7989814

Group type: EXPERIMENTAL
Intervention: Perioperative, high-dosage antibiotic administration
Number of subjects: 30

Group type: COMPARATOR
Intervention: Existing prophylactic regimen with longer intervals and postoperative antibiotics for 7 to 10 days
Number of subjects: 30
Study: 2690788

Group type: EXPERIMENTAL
Intervention: Sublingual nifedipine 10 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral captopril 50 mg
Number of subjects: 40
Study: 1137011

Group type: EXPERIMENTAL
Intervention: Unilateral ipsilateral trial
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Unilateral contralateral trial
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bilateral trial
Number of subjects: 30
Study: 31744374

Group type: EXPERIMENTAL
Intervention: Human papillomavirus self-sampling kit
Number of subjects: 116
Study: 31760819

Group type: EXPERIMENTAL
Intervention: Catheter ablation of AF
Number of subjects: 140

Group type: COMPARATOR
Intervention: Best medical therapy (BMT)
Number of subjects: 140
Study: 28026849

Group type: EXPERIMENTAL
Intervention: Presence of fabella (unilateral or bilateral)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Presence of fabella by body side
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Presence of fabella by gender
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Presence of fabella by age groups
Number of subjects: 500
Study: 26439038

Group type: EXPERIMENTAL
Intervention: Progesterone vaginal suppositories (400 mg, 200 mg 2 times per day) + Alpha Lipoic Acid (ALA) (600 mg, 300 mg 2 times per day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Progesterone vaginal suppositories (400 mg, 200 mg 2 times per day)
Number of subjects: 19
Study: 23504821

Group type: EXPERIMENTAL
Intervention: Everolimus plus exemestane (EVE + EXE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus exemestane (PBO + EXE)
Number of subjects: 0
Study: 21070328

Group type: EXPERIMENTAL
Intervention: IPI implants
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: I‐Plant implants
Number of subjects: 64

Group type: COMPARATOR
Intervention: Both implant systems (IPI and I‐Plant)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Transitional implants with good primary stability
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Primary stability
Number of subjects: 64

Group type: COMPARATOR
Intervention: Gender, kind of superstructure, location of the implant, tooth status of the opposing jaw, immediate prosthetic superstructure
Number of subjects: 64
Study: 19942103

Group type: EXPERIMENTAL
Intervention: Commercially available magnetic wrist strap
Number of subjects: 45

Group type: COMPARATOR
Intervention: Weak magnetic wrist strap
Number of subjects: 45

Group type: COMPARATOR
Intervention: Demagnetised wrist strap
Number of subjects: 45

Group type: COMPARATOR
Intervention: Copper bracelet
Number of subjects: 45
Study: 17273661

Group type: EXPERIMENTAL
Intervention: Thalidomide (300 mg daily for 30 days)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Pentoxifylline (1.2 g daily for 30 days)
Number of subjects: 44
Study: 15111077

Group type: EXPERIMENTAL
Intervention: Tendon Achilles lengthening (TAL)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Total contact casting (TCC)
Number of subjects: 28
Study: 11434591

Group type: EXPERIMENTAL
Intervention: Active coeliac disease (mean anti‐tTG, 21 AU)
Number of subjects: 1182

Group type: EXPERIMENTAL
Intervention: Treated coeliac disease (mean anti‐tTG, 5 AU)
Number of subjects: 1182

Group type: COMPARATOR
Intervention: Healthy controls (mean anti‐tTG, 3 AU)
Number of subjects: 1182

Group type: EXPERIMENTAL
Intervention: Eu‐tTG assay
Number of subjects: 1182
Study: 9534995

Group type: EXPERIMENTAL
Intervention: Hib conjugate vaccines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Booster dose at 1 year of age
Number of subjects: 0
Study: 7723004

Group type: EXPERIMENTAL
Intervention: Assessment battery used in Project MATCH
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strategies employed in Project MATCH
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Administration of assessment measures
Number of subjects: 0
Study: 2845707

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) 5000 anti-XaU injected every 24 hours
Number of subjects: 215

Group type: COMPARATOR
Intervention: Unfractionated heparin (UH) 5000 IU injected every 12 hours
Number of subjects: 215
Study: 1097977

Group type: EXPERIMENTAL
Intervention: Oral prostaglandin E2 (PGE2)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study: 30366741

Group type: EXPERIMENTAL
Intervention: 1:1.5 carbohydrate‐protein supplement (16g CHO/25g PRO) pre-training (PRE)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 1:1.5 carbohydrate‐protein supplement (16g CHO/25g PRO) post-training (POST)
Number of subjects: 43

Group type: COMPARATOR
Intervention: No supplement (CON)
Number of subjects: 43
Study: 29468530

Group type: EXPERIMENTAL
Intervention: Biomarker-guided therapy using NT-proBNP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 27886777

Group type: EXPERIMENTAL
Intervention: Resuscitation attempted or continued by Emergency Medical Service staff
Number of subjects: 11451

Group type: EXPERIMENTAL
Intervention: Resuscitation withheld due to futility
Number of subjects: 11451

Group type: EXPERIMENTAL
Intervention: Resuscitation withheld due to signs unequivocally associated with death
Number of subjects: 11451

Group type: EXPERIMENTAL
Intervention: Resuscitation withheld due to do-not-attempt-resuscitation decision
Number of subjects: 11451

Group type: EXPERIMENTAL
Intervention: Bystander CPR rates
Number of subjects: 11451
Study: 24841833

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 μg once daily via HandiHaler
Number of subjects: 457

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 457
Study: 21964557

Group type: EXPERIMENTAL
Intervention: Leftward optokinetic stimulation (OKS) during an auditory midline task.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Repetitive leftward optokinetic stimulation (OKS) with smooth pursuit eye movements as therapy.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Visual scanning therapy.
Number of subjects: 20
Study: 20659879

Group type: EXPERIMENTAL
Intervention: Chest Pain Unit (CPU) care
Number of subjects: 2389

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 2389
Study: 17559376

Group type: EXPERIMENTAL
Intervention: Somatostatin infusion for 12 hours (SOM1)
Number of subjects: 3130

Group type: EXPERIMENTAL
Intervention: Somatostatin bolus (SOM3)
Number of subjects: 3130

Group type: EXPERIMENTAL
Intervention: Gabexate infusion for 12 hours (GAB1)
Number of subjects: 3130

Group type: COMPARATOR
Intervention: Somatostatin infusion for less than 12 hours (SOM2)
Number of subjects: 3130

Group type: COMPARATOR
Intervention: Gabexate infusion for less than 12 hours (GAB2)
Number of subjects: 3130
Study: 16269290

Group type: EXPERIMENTAL
Intervention: Pancreatoduodenectomy with extended lymphadenectomy (PD/ELND)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Standard pancreatoduodenectomy (PD)
Number of subjects: 132
Study: 12127377

Group type: EXPERIMENTAL
Intervention: Supervised exercise training programme over 6 weeks (n=15)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (n=10)
Number of subjects: 25
Study: 10597956

Group type: EXPERIMENTAL
Intervention: Folic acid supplement (2.5 mg or 1.0 mg)
Number of subjects: 14021

Group type: COMPARATOR
Intervention: No folic acid supplement
Number of subjects: 14021
Study: 8598594

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (one of four regimens: streptokinase with subcutaneous heparin; streptokinase with intravenous heparin; streptokinase plus alteplase with intravenous heparin; accelerated alteplase with intravenous heparin)
Number of subjects: 41021

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (alteplase)
Number of subjects: 41021

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 41021
Study: 2303145

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone (MPA)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Norethisterone (NET)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 6113192

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg bd
Number of subjects: 103

Group type: COMPARATOR
Intervention: Cimetidine 200 mg tds and 400 mg nocte
Number of subjects: 103
Study: 31126541

Group type: EXPERIMENTAL
Intervention: Salix extract (400 mg daily)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Mefenamic acid (750 mg daily)
Number of subjects: 96
Study: 27819804

Group type: EXPERIMENTAL
Intervention: Mind Subtraction Meditation (MSM)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Self-management education (SME)
Number of subjects: 46
Study: 26482774

Group type: EXPERIMENTAL
Intervention: Annual school-based deworming (SBD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Annual community-based deworming (CBD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biannual community-based deworming (CBD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Annual SBD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Annual CBD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Biannual CBD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study: 25052890

Group type: EXPERIMENTAL
Intervention: 5 mg of folic acid added to ADM for 12 weeks
Number of subjects: 475

Group type: COMPARATOR
Intervention: Placebo added to ADM for 12 weeks
Number of subjects: 475
Study: 23171320

Group type: EXPERIMENTAL
Intervention: IFCR‐L (Intermittent fasting combined with calorie restriction and liquid diet)
Number of subjects: 54

Group type: COMPARATOR
Intervention: IFCR‐F (Intermittent fasting combined with calorie restriction and food diet)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: IFCR‐L
Number of subjects: 54

Group type: COMPARATOR
Intervention: IFCR‐F
Number of subjects: 54
Study: 20951300

Group type: EXPERIMENTAL
Intervention: White mineral trioxide aggregate (WMTA) at pH 8.4
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: White mineral trioxide aggregate (WMTA) at pH 10.4
Number of subjects: 80
Study: 17967379

Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parenteral nutrition
Number of subjects: 0